NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis → [Webinar] A Deep Dive into Options Volatility: Skew & Relative Value (From OIC) (Ad) Free LGND Stock Alerts $85.94 -0.18 (-0.21%) (As of 10:15 AM ET) Add Compare Share Share Today's Range$84.05▼$86.4050-Day Range$68.53▼$86.1252-Week Range$49.24▼$94.57Volume10,377 shsAverage Volume160,356 shsMarket Capitalization$1.52 billionP/E Ratio31.25Dividend YieldN/APrice Target$116.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ligand Pharmaceuticals alerts: Email Address Ligand Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside35.8% Upside$116.33 Price TargetShort InterestHealthy4.49% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.66Based on 21 Articles This WeekInsider TradingSelling Shares$153,034 Sold Last QuarterProj. Earnings Growth16.72%From $3.41 to $3.98 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.93 out of 5 starsMedical Sector36th out of 915 stocksPharmaceutical Preparations Industry11th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Ligand Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.49% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 3.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 3.1 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $153,034.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 16.72% in the coming year, from $3.41 to $3.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 31.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 31.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 188.83.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityCharles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Ligand Pharmaceuticals Stock (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Read More LGND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Stock News HeadlinesMay 9, 2024 | finance.yahoo.comLigand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)May 9, 2024 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Trading 7.3% Higher Following Strong EarningsMay 10, 2024 | Unstoppable Prosperity (Ad)Charles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 8, 2024 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 8, 2024 | finance.yahoo.comQ1 2024 Agenus Inc Earnings CallMay 7, 2024 | investorplace.comLGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | markets.businessinsider.comLigand Pharmaceuticals Inc Q1 Profit Increases, beats estimatesMay 10, 2024 | Unstoppable Prosperity (Ad)Charles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 7, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Reports Mixed Q1 2024 Results: Misses Revenue Estimates but ...May 7, 2024 | seekingalpha.comLigand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | businesswire.comLigand Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comLigand Enters Into $100 Mln Royalty Financing Agreement With Agenus For BOT/BAL Clinical Dvpt.May 7, 2024 | businesswire.comLigand and Agenus Enter Into $100 Million Royalty Financing AgreementMay 5, 2024 | americanbankingnews.comLigand Pharmaceuticals (LGND) Set to Announce Quarterly Earnings on TuesdayApril 23, 2024 | businesswire.comLigand to Report First Quarter 2024 Financial Results on May 7, 2024April 17, 2024 | finance.yahoo.comWall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should KnowApril 9, 2024 | finance.yahoo.comCan Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Performance Keep Up Given Its Mixed Bag Of Fundamentals?April 8, 2024 | investorplace.com7 Small-Cap Stocks for the Thinking SpeculatorApril 8, 2024 | businesswire.comLigand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures ConferenceMarch 28, 2024 | finance.yahoo.comLigand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?March 27, 2024 | msn.comLigand Pharmaceuticals gains amid bullish investor pitchMarch 16, 2024 | finance.yahoo.comLGND Apr 2024 70.000 putMarch 16, 2024 | finance.yahoo.comLGND Apr 2024 110.000 callMarch 6, 2024 | uk.finance.yahoo.comLigand Pharmaceuticals Incorporated (LGND)March 5, 2024 | businesswire.comLigand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare ConferenceMarch 4, 2024 | businesswire.comLigand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/10/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees58Year FoundedN/APrice Target and Rating Average Stock Price Target$116.33 High Stock Price Target$144.00 Low Stock Price Target$95.00 Potential Upside/Downside+35.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.75 Trailing P/E Ratio31.15 Forward P/E Ratio25.12 P/E GrowthN/ANet Income$52.15 million Net Margins37.80% Pretax Margin48.48% Return on Equity11.98% Return on Assets10.27% Debt Debt-to-Equity RatioN/A Current Ratio14.15 Quick Ratio12.72 Sales & Book Value Annual Sales$131.31 million Price / Sales11.55 Cash Flow$5.80 per share Price / Cash Flow14.77 Book Value$40.39 per share Price / Book2.12Miscellaneous Outstanding Shares17,705,000Free Float15,864,000Market Cap$1.52 billion OptionableOptionable Beta1.01 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Matthew E. Korenberg (Age 49)President & COO Comp: $831.77kMr. Octavio Espinoza (Age 53)Chief Financial Officer Comp: $613.59kMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Comp: $614.87kMr. Scott M. Plesha (Age 59)Chief Executive Officer Mr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More ExecutivesKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDMannKindNASDAQ:MNKDDynavax TechnologiesNASDAQ:DVAXInnovivaNASDAQ:INVAOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemSold 690 shares on 5/9/2024Ownership: 0.023%William Blair Investment Management LLCBought 1,905 shares on 5/8/2024Ownership: 1.069%ProShare Advisors LLCBought 363 shares on 5/8/2024Ownership: 0.026%Everence Capital Management Inc.Bought 2,760 shares on 5/8/2024Ownership: 0.016%Headlands Technologies LLCSold 341 shares on 5/8/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions LGND Stock Analysis - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price target for 2024? 3 Wall Street analysts have issued 12 month price objectives for Ligand Pharmaceuticals' shares. Their LGND share price targets range from $95.00 to $144.00. On average, they expect the company's share price to reach $116.33 in the next twelve months. This suggests a possible upside of 35.8% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2024? Ligand Pharmaceuticals' stock was trading at $71.42 at the beginning of the year. Since then, LGND shares have increased by 19.9% and is now trading at $85.66. View the best growth stocks for 2024 here. Are investors shorting Ligand Pharmaceuticals? Ligand Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 826,600 shares, an increase of 23.0% from the March 31st total of 672,100 shares. Based on an average daily trading volume, of 170,300 shares, the days-to-cover ratio is currently 4.9 days. Approximately 5.0% of the company's stock are short sold. View Ligand Pharmaceuticals' Short Interest. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported $3.84 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $3.01. The biotechnology company had revenue of $30.90 million for the quarter, compared to analysts' expectations of $27.92 million. Ligand Pharmaceuticals had a net margin of 37.80% and a trailing twelve-month return on equity of 11.98%. The firm's revenue for the quarter was down 29.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.96 EPS. What ETFs hold Ligand Pharmaceuticals' stock? ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Tema Global Royalties ETF (ROYA), Virtus LifeSci Biotech Products ETF (BBP), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Franklin Genomic Advancements ETF (HELX). What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of 4.250-4.750 for the period, compared to the consensus estimate of 4.440. The company issued revenue guidance of $130.0 million-$142.0 million, compared to the consensus revenue estimate of $137.7 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Villere ST Denis J & Co. LLC (2.77%), Rice Hall James & Associates LLC (1.58%), William Blair Investment Management LLC (1.07%), Principal Financial Group Inc. (0.52%), Allspring Global Investments Holdings LLC (0.48%) and Russell Investments Group Ltd. (0.41%). Insiders that own company stock include Andrew Reardon, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LGND) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
